AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies, with the goal of achieving functional cure for chronic hepatitis B (CHB) infection, today announced significant progress in the clinical development of its leading candidate, AHB-137. This innovative unconjugated antisense oligonucleotide (ASO) targets all HBV mRNA, positioning it as a potential backbone of novel therapies to treat CHB for functional cure.
As of the report date, a total of 193 participants, including 101 CHB patients, have been enrolled in the AHB-137 clinical studies, generating a substantial dataset for the drug’s safety and efficacy profile, and marking significant progress since our last update in February.
China Phase 1b study has been successfully completed.
Global Phase 1b patient enrollment has concluded.
Clinical data from both Phase 1 studies were presented in two late-breaker posters at EASL 2024.
Phase 2a study in China has completed patient enrollment.
Large-scale manufacturing of AHB-137 drug product has been successfully completed.
